Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results.
Saved in:
| Title: | Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. |
|---|---|
| Authors: | Gener-Ricos G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Haddad FG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Issa GC; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Skinner J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Jabbour E; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Kantarjian H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: hkantarjian@mdanderson.org. |
| Source: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Oct; Vol. 23 (10), pp. 742-748. Date of Electronic Publication: 2023 May 23. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
